EP1551964A4 - METHOD AND COMPOSITIONS FOR EXTENDING LIFE AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS - Google Patents

METHOD AND COMPOSITIONS FOR EXTENDING LIFE AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS

Info

Publication number
EP1551964A4
EP1551964A4 EP03788377A EP03788377A EP1551964A4 EP 1551964 A4 EP1551964 A4 EP 1551964A4 EP 03788377 A EP03788377 A EP 03788377A EP 03788377 A EP03788377 A EP 03788377A EP 1551964 A4 EP1551964 A4 EP 1551964A4
Authority
EP
European Patent Office
Prior art keywords
lifetime
organisms
compositions
cells
extend
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03788377A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1551964A2 (en
Inventor
David A Sinclair
Kevin J Bitterman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Priority to EP11179088A priority Critical patent/EP2431480A3/en
Publication of EP1551964A2 publication Critical patent/EP1551964A2/en
Publication of EP1551964A4 publication Critical patent/EP1551964A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
EP03788377A 2002-08-09 2003-08-08 METHOD AND COMPOSITIONS FOR EXTENDING LIFE AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS Withdrawn EP1551964A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11179088A EP2431480A3 (en) 2002-08-09 2003-08-08 Methods and compositions for increasing the stress resistance of cells and organisms

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40225402P 2002-08-09 2002-08-09
US402254P 2002-08-09
US42861402P 2002-11-22 2002-11-22
US428614P 2002-11-22
PCT/US2003/025016 WO2004016726A2 (en) 2002-08-09 2003-08-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Publications (2)

Publication Number Publication Date
EP1551964A2 EP1551964A2 (en) 2005-07-13
EP1551964A4 true EP1551964A4 (en) 2010-07-28

Family

ID=31720582

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03788377A Withdrawn EP1551964A4 (en) 2002-08-09 2003-08-08 METHOD AND COMPOSITIONS FOR EXTENDING LIFE AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS
EP11179088A Withdrawn EP2431480A3 (en) 2002-08-09 2003-08-08 Methods and compositions for increasing the stress resistance of cells and organisms

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP11179088A Withdrawn EP2431480A3 (en) 2002-08-09 2003-08-08 Methods and compositions for increasing the stress resistance of cells and organisms

Country Status (5)

Country Link
EP (2) EP1551964A4 (https=)
JP (3) JP2005535342A (https=)
AU (2) AU2003264037B2 (https=)
CA (2) CA2421269A1 (https=)
WO (1) WO2004016726A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
CA2529510A1 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
CA2553542A1 (en) * 2003-10-31 2005-04-30 Robarts Research Institute Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
PL1794306T3 (pl) 2004-09-24 2010-05-31 Bayer Cropscience Nv Rośliny oporne na stres
EP1844157A4 (en) * 2005-01-25 2009-11-25 Univ Johns Hopkins STRATEGIES FOR THE DESIGN OF SUBSTANCES TO BE TAKEN ON THE SIR2 FAMILY OF ENZYMES
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP1893759B1 (en) * 2005-06-15 2009-08-12 Bayer BioScience N.V. Methods for increasing the resistance of plants to hypoxic conditions
US8158856B2 (en) * 2006-03-21 2012-04-17 Bayer Cropscience Nv Stress resistant plants
PL2103212T3 (pl) 2006-12-11 2015-03-31 Okayama Barley Genome Tech Co Ltd Regulator wzrostu roślin i jego zastosowanie
CN101686669B (zh) 2007-11-13 2014-03-26 独立行政法人科学技术振兴机构 用于培育糖度提高的植物体的组合物及其用途
JP5570731B2 (ja) * 2008-02-28 2014-08-13 旭化成ファーマ株式会社 ピロリン酸の測定方法
EP2259782A4 (en) 2008-03-03 2013-01-23 Nad Life Pty Ltd PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHOD FOR THEIR USE IN THE TREATMENT OF CELL DISEASES
JP2011115098A (ja) * 2009-12-04 2011-06-16 Nippon Menaade Keshohin Kk 加齢による皮膚明度の低下を予測する皮膚評価方法
WO2013088956A1 (ja) 2011-12-12 2013-06-20 岡山県 植物のアミノ酸含量を高めるための化合物およびその利用
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
WO2015069860A1 (en) * 2013-11-06 2015-05-14 President And Fellows Of Harvard College Biological production of nad precursors and analogs
JP2017518306A (ja) 2014-06-02 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用
AU2015270090A1 (en) 2014-06-06 2016-12-22 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
JP6623015B2 (ja) * 2014-09-29 2019-12-18 国立研究開発法人理化学研究所 植物の耐塩性向上剤
WO2020097116A1 (en) * 2018-11-05 2020-05-14 Rejuvenation Therapeutics Compositions and methods for culturing yeast cells
US20220324899A1 (en) * 2019-08-14 2022-10-13 Metro International Biotech, Llc Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide
CN111394268B (zh) * 2019-12-20 2021-06-18 合肥康诺生物制药有限公司 基因工程菌及其构建方法、应用，生产nad+的方法
CN112451673A (zh) * 2020-12-10 2021-03-09 汤臣倍健股份有限公司 线粒体功能干预材料在制备改善线粒体功能的保健品或药品中的应用及其筛选方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
WO1989005345A1 (en) 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JP3249516B2 (ja) 1990-10-31 2002-01-21 ソマティクス セラピー コーポレイション 遺伝子治療のためのレトロウイルスのベクター
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
ATE245703T1 (de) 1992-09-22 2003-08-15 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
EP0746625B1 (en) 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targetable vector particles
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
WO1996013597A2 (en) 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
NZ300387A (en) 1994-12-12 2001-07-27 Genetic Therapy Inc Adenoviral vector modified to reduce host immune and inflammatory responses and its use in gene therapy treatment
DK0811073T3 (da) 1995-02-24 2007-05-21 Univ Pennsylvania Avendelse af immunmodulatorer til fremstilling af medikamenter til inhibering af immunresponser mod co-administrerede rekombinanter
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
AU2001294173A1 (en) * 2000-10-03 2002-04-15 Takara Bio Inc. Method of screening physiologically active substance
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
PL1794306T3 (pl) * 2004-09-24 2010-05-31 Bayer Cropscience Nv Rośliny oporne na stres
US9515947B1 (en) 2013-03-15 2016-12-06 EMC IP Holding Company LLC Method and system for providing a virtual network-aware storage array
KR20160071054A (ko) 2014-12-11 2016-06-21 에스케이하이닉스 주식회사 반도체 메모리 장치 및 그의 동작 방법
US9609948B2 (en) 2015-04-28 2017-04-04 Qianglong Furniture Co., Ltd. Rotating armrest apparatus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CROWLEY C L ET AL: "The NAD+ precursors, nicotinic acid and nicotinamide protect cells against apoptosis induced by a multiple stress inducer, deoxycholate", CELL DEATH AND DIFFERENTIATION, vol. 7, no. 3, March 2000 (2000-03-01), Great Britain, pages 314 - 326, XP000953224, ISSN: 1350-9047, DOI: 10.1038/sj.cdd.4400658 *
DRAGOVIC J ET AL: "Phase I/II study of pentoxifylline and nicotinamide in combination with radiation therapy in locally advanced cancers", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 24, no. SUPPL. 1, 1992, & 34TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY, SAN DIEGO, CALIF, pages 272 - 273, XP026844395, ISSN: 0360-3016 *
GOTOH HIROKO: "Inhibitory effects of nicotinamide on the growth of transplanted murine breast cancer and urethane-initiated lung tumorigenesis in mice", VITAMINS, vol. 67, no. 9, 1993, KYOTO, pages 469 - 479, XP008036628, ISSN: 0006-386X *
KNIP M ET AL: "Safety of high-dose nicotinamide: A review", DIABETOLOGIA, vol. 43, no. 11, November 2000 (2000-11-01), Germany, pages 1337 - 1345, XP009134696, ISSN: 0012-186X, DOI: 10.1007/s001250051536 *
SESTILI P ET AL.: "Structural requirements for inhibitors of poly(ADP-ribose) polymerase.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, LNKD- PUBMED:2123880, vol. 116, no. 6, 1990, GERMANY, pages 615 - 622, XP009134778, ISSN: 0171-5216 *

Also Published As

Publication number Publication date
JP6602561B2 (ja) 2019-11-06
WO2004016726A2 (en) 2004-02-26
EP2431480A2 (en) 2012-03-21
JP2015198665A (ja) 2015-11-12
AU2010219395A1 (en) 2010-09-30
CA2421269A1 (en) 2004-02-09
AU2003264037A1 (en) 2004-03-03
WO2004016726A3 (en) 2005-05-19
AU2010219395B2 (en) 2011-07-14
EP2431480A3 (en) 2012-09-05
WO2004016726A9 (en) 2005-08-04
EP1551964A2 (en) 2005-07-13
JP2005535342A (ja) 2005-11-24
CA2495185A1 (en) 2004-02-26
AU2003264037B2 (en) 2010-06-17
JP2011015682A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
EP1551964A4 (en) METHOD AND COMPOSITIONS FOR EXTENDING LIFE AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS
EP1578447A4 (en) METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION
EP1644009A4 (en) COMPOSITIONS AND METHOD FOR INCREASING TELOMERASE ACTIVITY
EP1553151A4 (en) HYDROGEN AND OLEOPHOBIC AGENTS
BRPI0317545A2 (pt) "composições de poli-hema de baixa polidispersão"
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
IL225633B (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
FI20021947A7 (fi) Menetelmä triglyseridien rasvahappoketjukoostumuksen säätämiseksi sekä menetelmän käyttö
EP1771786A4 (en) SAMPLE PROCESSING SIMULTANEOUS
BRPI0415741B1 (pt) composições de tabaco e métodos de fabricação de uma composição de tabaco
DK1148875T3 (da) Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer
EP1638977A4 (en) SALINOSPORAMIDES AND METHOD OF USE THEREOF
EP1594544A4 (en) ORAL COMPOSITIONS OF FENRETINIDE WITH INCREASED BIOAVAILABILITY AND METHOD FOR THE APPLICATION THEREOF
DE502004004173D1 (de) Silber-legierung und deren Verwendung
EP1225231A4 (en) RESISTANCE TO ENVIRONMENTAL STRESS
EP1607088A4 (en) COMPOSITION WITH CONTROLLED RELEASE
EP1609837A4 (en) FRICTIONAL MATERIAL COMPOSITION AND FRICTIONAL MATERIAL MANUFACTURED THEREOF
DE602004000994D1 (de) Co-Ni-Al Gedächtnislegierung und Verfahren zu deren Herstellung
EP1827464A4 (en) COMPOSITIONS ON ZINC BASE AND METHOD OF USE
EP1663255A4 (en) WITHANAMID AND WITHANOLID COMPOSITIONS AND APPLICATION METHOD THEREFOR
DE60309794D1 (de) Moschuszusammmensetzungen mit fruchtartigen Geruchsnoten
EP1409454A4 (en) INCREASED BIOVERABILITY OF CAROTENOIDS
EP1633749A4 (en) Deazaflavin compounds and methods of use thereof
EP1481933A4 (en) Emergency stop tester of elevator
EP1578393A4 (en) PRIMARY RAT HEPATOCYTIC TOXICITY MODELING

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050308

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100628

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20100622BHEP

Ipc: C07K 14/47 20060101ALI20100622BHEP

Ipc: A61K 38/45 20060101ALI20100622BHEP

Ipc: A01N 25/00 20060101ALI20100622BHEP

Ipc: C07H 21/04 20060101ALI20100622BHEP

Ipc: C12Q 1/58 20060101ALI20100622BHEP

Ipc: C12Q 1/00 20060101ALI20100622BHEP

Ipc: C12N 1/20 20060101ALI20100622BHEP

Ipc: C12N 9/12 20060101ALI20100622BHEP

Ipc: G01N 33/573 20060101AFI20100622BHEP

17Q First examination report despatched

Effective date: 20110217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110830